Nkarta Inc. (NKTX) Next Earnings Date & Expected ±12.5% Move

The per the Roarable RQD rating, NKTX carries an RQD Score of 31 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the stock scores 4/20 on the fundamental cash engine (ROIC -35%; FCF yield 0%), 5/20 on whale 13F flow (institutional accumulation and options positioning), 5/20 on insider conviction (SEC Form 4 and Congressional PTR cluster flow), 10/20 on macro regime fit (Beta 1.0; sector sensitivity), and 7/20 on forensic balance sheet (Altman Z 0.2; Piotroski F 3/9; Debt/Equity 0.5).

For a prospective investor evaluating the stock today, the rating points to weak internal cash generation, as the cash engine pillar is the lowest-scoring component and the source reports no revenue, zero margins, and negative free cash flow across the reported periods. The forensic pillar reflects balance-sheet stress markers, with a low Altman Z-score and a weak Piotroski reading. Institutional and insider pillars are also low, indicating limited observable conviction signals in the provided data. Upside drivers, if any, would have to come from outside the metrics captured here, since the rating itself indicates the reported fundamentals do not currently support a cash-based valuation. The beta of 1.0 places the stock in line with the broader market on volatility, but the rating's macro-fit score is only 10/20, so sector sensitivity is a relevant consideration.

Per the SEC financials, the company reported zero revenue and operating losses in each of the three periods, with the gross, operating, and net margins all shown as 0%. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 0.2, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash was $39.6M at FY 2025 and $27.9M at FY 2024, and the source does not provide cash or debt for FY 2023 or debt for the other periods. Taken together, these figures describe a company reporting continuing losses and negative free cash flow with a low Altman Z-Score.

Per the recent news and catalysts section, six items were tagged as market wire, all related to NKTX. Headlines include a TradingView estimates report, a Yahoo! Finance seasonal returns chart, an H.C. Wainwright initiation of coverage with a buy rating (reported via Investing.com India), a Simply Wall St article on cash allocation, and two technical-level items referencing support and resistance around $2.45 and $2.71 and a retracement near $2.21. These items are all classified YELLOW by the source. The technical reports cite prices ($2.58, $2.21) that differ from the current price of $1.66 in the market data section, so their timing and reliability cannot be reconciled from the source. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

• What specific products, clinical programs, or revenue sources does the company have, given that reported revenue is $0.0M across periods?
• What are the FY 2023 cash and debt figures and the debt balances for all periods, which the source leaves unreported?
• What is the company's cash runway relative to the reported negative free cash flow of $-89.9M in FY 2025?
• What is the basis for the reported H.C. Wainwright buy rating, and does it reflect a formal price target?
• Which of the technical price levels cited in the news items (such as $2.58) relate to the current $1.66 price, and over what time frame?